Last edition
News about "Alex Zhavoronkov"
Insilico Medicine Receives USD 5 Million from Menarini
Insilico received an additional $5 million milestone from Menarini following first-in-patient dosing in a Phase I trial of MEN2501, a generative AI-designed KIF18A inhibitor for chromosomally unstable solid tumours.
Alex Zhavoronkov | 05/02/2026 | By News Bureau | 118
Insilico Medicine and Qilu Pharmaceutical Sign USD 120 Million Cardiometabolic Drug Deal
According to the agreement, Insilico Medicine will utilise its proprietary Pharma.AI platform to focus on the design and optimisation of novel small molecules for treating metabolic diseases, while Qilu Pharmaceutical Group will be responsible for subsequent development and commercialisation procedures.
Alex Zhavoronkov | 28/01/2026 | By News Bureau | 143
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy